Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease
Wilson E, Young C, Benitez J, Vandijck M, Swarovski M, Shahid M, Corso N, Kennedy G, Trelle A, Channappa D, Belnap M, Lind B, Le Bastard N, Quinn J, Nairn A, Kerchner G, Sha S, Wagner A, Henderson V, Longo F, Wyss‐Coray T, Poston K, Mormino E, Andreasson K. Diagnostic and Prognostic Performance of the Modified Lumipulse pTau 181 Assay in Plasma for Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.060879.Peer-Reviewed Original ResearchAlzheimer's Disease Research CenterPtau-181Disease Research CenterAlzheimer's diseaseCohort 1Positron emission tomographyCohort 2Prognostic performanceAntibody combinationsAD participantsAβ42/Aβ40 ratioPreclinical Alzheimer's diseaseClinical AD diagnosisPlasma p-tau181Longitudinal cognitive declineTau pathologyAD pathologyCSF biomarkersTau-PETP-tau181Outcome measuresPhosphorylated tauPET biomarkersAβ40 ratioCognitive declinePerformance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson E, Young C, Ramos Benitez J, Swarovski M, Feinstein I, Vandijck M, Le Guen Y, Kasireddy N, Shahid M, Corso N, Wang Q, Kennedy G, Trelle A, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis M, Le Bastard N, Quinn J, van Dyck C, Nairn A, Fredericks C, Tian L, Kerchner G, Montine T, Sha S, Davidzon G, Henderson V, Longo F, Greicius M, Wagner A, Wyss-Coray T, Poston K, Mormino E, Andreasson K. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease. Alzheimer's Research & Therapy 2022, 14: 172. PMID: 36371232, PMCID: PMC9652927, DOI: 10.1186/s13195-022-01116-2.Peer-Reviewed Original ResearchConceptsPlasma p-tau181Alzheimer's Disease Research CenterP-tau181Disease Research CenterAlzheimer's diseasePositron emission tomographyAD dementiaBlood-based biomarker assaysAmyloid positron emission tomographyTreatment monitoringNovel blood-based biomarkersCSF p-tau181P-tau181 concentrationsDisease-modifying therapiesAβ42/Aβ40 ratioBlood-based biomarkersClinical AD diagnosisDetection of ADMild cognitive impairmentStudy cohortCSF biomarkersPlasma levelsAD groupPrognostic performanceCDR sum